VERAgene tests for microdeletions and single gene diseases which, unlike aneuploidies, do not have age associated risks, and they do not have biomarkers for early detection. VERAgene can accurately screen for these conditions from 10 weeks of pregnancy, giving new parents insight into their baby's health and take informed decisions about possible treatment and management.